DeWire et al. conducted a phase I/II trial to identify the efficacy of ribociclib (CDK4/6-inhibitor) in newly diagnosed DIPG patients as an adjuvant monotherapy after radiotherapy. Here, CDK4 is linked to diffuse intrinsic pontine glioma.